Abstract

This research aimed to investigate the expression and function of FAM83A in the proliferation and metastasis in head and neck squamous cell carcinoma (HNSCC). FAM83A mRNA and protein expressions in HNSCC were detected in primary HNSCC samples and cell lines. The associations between FAM83A expression and clinicopathologic variables were evaluated through tissue microarrays. Besides, FAM83A knockdown and overexpression cell lines were constructed to assess cell growth and metastasis in vitro and the relationship between FAM83A and epithelial-mesenchymal transition (EMT). Furthermore, two models of xenograft tumors in nude mice were used to assess the tumorigenicity and metastasis ability of FAM83A in vivo. In the present study, overexpression of FAM83A in HNSCC samples was significantly associated with tumor size, lymph node status and clinical tumor stages. Mechanically, FAM83A could promote HNSCC cell growth and metastasis by inducing EMT via activating Wnt/β-catenin signaling pathway. Rescue experiment demonstrated the inhibition of β-catenin could counteract the function of FAM83A. Also, the FAM83A knockdown could suppress tumor growth and distant metastasis in the xenograft animal models of HNSCC. In conclusion, this study identifies FAM83A as an oncogene of HNSCC. This study provides new insights into the molecular pathways that contribute to EMT in HNSCC. We revealed a previously unknown FAM83A-Wnt-β-catenin signaling axis involved in the EMT of HNSCC. There may be a potential bi-directional signaling loop between FAM83A and Wnt/β-catenin signaling pathway in HNSCC.

Keywords:  FAM83A, Head Neck Squamous Cell Carcinoma, Wnt/β-catenin Signaling, Proliferation, Metastasis

Introduction

In recent years, head and neck squamous cell carcinoma (HNSCC) is one of the most common cancers worldwide, with more than 350,000 cancer-related deaths per year even though combined and multidisciplinary therapy has greatly advanced [1, 2]. Therefore, more efforts should be made to explore the cellular and molecular mechanism of HNSCC tumorigenesis. Thus, the identification of new therapeutic targets for HNSCC is urgently needed for clinicians.

As the smallest member of the FAM83 family (FAM83A to H), family with sequence similarity 83, member A (FAM83A), is located on chromosome 8q24. In 2005, FAM83A with the conserved DUF1669 domain at its N-terminus, was firstly reported as a potential cancer biomarker involved in tumor progression [3]. Prior studies have suggested that FAM83A is abnormally expressed and involved in the progression of multiple human cancers [4–13]. It is also reported FAM83A can
be a diagnostic and prognostic marker of non-small cell lung cancer and is closely related to tumor histology and signal transduction [14, 15]. FAM83A signaling can also stimulate epithelial-mesenchymal transition (EMT) by triggering the PI3K/AKT/Snail pathway in non-small cell lung cancer [16]. Furthermore, FAM83A/PD-L1 co-expression correlates with poor prognosis in lung adenocarcinoma, and FAM83A drives PD-L1 expression via ERK signaling, thus causing tumor immune escape [13].

DUF1669 domain mediates the interaction with the α, δ or ε isoforms of the CK1 family of Ser/Thr protein kinases [17]. The FAM83 proteins can interact with CK1α, and FAM83A, B, E and H also interact with CK1δ and ε isoforms. CK1α, δ and ε isoforms have been involved in cellular processes including Wnt signaling, mitosis, and DNA damage responses [18–21]. It has been previously reported that FAM83F and FAM83G can regulate canonical Wnt signaling through an interaction with CK1α [22]. Recent studies have shown that FAM83A also regulates canonical Wnt/β-catenin signaling pathway in EMT of lung cancer [23]. However, whether FAM83A can regulate canonical Wnt signaling in HNSCC remains unknown. Here, we aim to clarify the role and mechanism of FAM83A in the proliferation and metastasis of HNSCC cells, thus providing evidence for more potential therapeutic targets for HNSCC.

Materials and methods

Patients

In brief, 242 patients including 148 males and 94 females, who underwent surgery and were diagnosed as primary HNSCC from 2009 to 2014 in the Affiliated Stomatological Hospital of Nanjing Medical University, were recruited. 242 HNSCC samples and 12 HNSCC adjacent normal tissues were used to make tissue microarrays [24]. The clinicopathologic information including age, gender, tumor size, lymph node status, histological grade, clinical stage and follow-up visits were obtained from the patients’ electronic medical records and follow-up visits. Besides, we collected 48 pairs of fresh HNSCC tissues and adjacent normal tissues to extract mRNA and chose 10 pairs of them to examine FAM83A expression. All experiments were in accordance with the Institutional Review Board of the Nanjing Medical University and complied with the Declaration of Helsinki (Approval ID 2019343).

Immunohistochemistry and evaluation of immunoreactivity

The procedure of immunohistochemistry (IHC) was carried out as we described previously [25]. The stained slides were analyzed by two pathologists separately. FAM83A staining was grouped by combining intensity score (IS) and positive score (PS). IS was divided into four groups: negative (0), weak (1), moderate (2), and strong (3), whereas PS was categorized into four grades: negative (0), <10% (1), 11%-50% (2), 51%-80% (3), and >80% (4). We then calculated the immunoreactive score (IRS) by multiplying IS and PS. The final IRSs were divided into two groups: low FAM83A expression (≤4), and high FAM83A expression (>4). The antibody used in IHC was FAM83A (1:100; Proteintech, Rosemont, IL, USA).

Cell lines and cell culture

The human normal oral keratinocytes (HOK) and the human HNSCC cell lines including CAL27, FADU, HN4, HN6 SCC-9, and SCC-25 cell, were purchased from China Center for Type Culture Collection (Shanghai, China), CAL27 and HOK were cultured in DMEM medium (Gibco). FADU, HN4, and HN6 were cultured in DMEM/F12 medium (Gibco). All culture medium contained 10% fetal bovine serum (FBS, Sciencell) and 1% penicillin/streptomycin. Cells were cultured in a humidified incubator containing 5% CO2 at 37 °C.

Cell transfection

The human FAM83A lentivirus targeting to upregulate FAM83A (LV-FAM83A), the negative control (LV-NC), the shRNA lentivirus targeting to knock down FAM83A (shFAM83A: 5’-GGAGUGUGAAAGAGAGAATT-3’), and the shRNA negative control lentivirus (shNC) were ordered from GeneChem Co., Ltd (Shanghai, China). Small interfere RNA (siRNA) of β-catenin (siβ-catenin: 5’-GGACACAGCAGCAUUUGUTT-3’) purchased from GenePharma Co., Ltd (Shanghai, China) was used to silence β-catenin expression. A plasmid containing the β-catenin cDNA sequence (GeneCoperia, China) was used to overexpress β-catenin expression. XAV-939 (Selleck, USA), a small-molecule inhibitor, resolved with DMSO, was used to suppress exogenous β-catenin expression.

Real-time PCR and western blotting assays

Real-time RT-PCR and western blotting assays were carried out in accordance with standard process as we described previously [25]. Nuclear and cytoplasmic protein extraction from cells is in accordance with the TRIZOL reagent (Invitrogen) manufacturer’s protocol. The primers were used as follows, FAM83A: forward 5’-ATCCGGAGTGGGAAGAGAG-3’, reverse 5’-TCC AGACAAGCAAAATCTCCAGT-3’, E-cadherin: forward 5’-GCCCTATGATTCTCTGCCTG-3’, reverse 5’-GCCCATCTCTTCAAGTATGTC-3’, N-cadherin: forward 5’-GTGAGCCCTGCAGATTTTAAGGTG-3’, reverse 5’-GTGGGTTCAGGGCTCATTTCCT-3’, Vimentin: forward 5’-CTGAGATTTCTCCCT
CTGGTT-3'; reverse 5'-TCGTGTGCTGAGAAGTTTGC
TGTT-3'; Snail: forward 5'- GCAGAGACACAGAAACCGAGA
AAA-3'; β-catenin: forward 5'-TGCAAAACTCGC
AAAATGACGAGG-3'; reverse 5'- CGCATGATAAGC
TTTGCTCTGA-3'; c-myc: forward 5'-CCACGA
AATTCTGTTT-3'; Snail: forward 5'-TTC
TCACTGACCAATGGAAATTCC-3', reverse 5'-
GCA GAG GAC ACA GAA CCGAGAAA-3'; β-catenin:
TGA CAA AAC TGC TAA ATG ACG AGG -3', reverse 5'-
CAG CATCTCATAAAC
AGTCTACTC-3'; GAPDH: forward 5'-GACG
GATGG-3'. Primary antibodies were as follows: GAPDH
(1:1000; Proteintech, Rosemont, IL, USA), FAM83A
(1:1000; Proteintech, Rosemont, IL, USA), E-cadherin
(1:1000; CST), N-cadherin(1:1000; CST), Vimentin
(1:1000; CST), Snail (1:1000; Proteintech, Rosemont,
IL, USA), β-catenin (1:1000; CST), Phospho-β-catenin
(1:1000; CST), Lamin B1 (1:1000; CST), and Cyclin D1
(1:1000; CST).

Cell migration and invasion assays
For the migration assay, 8 × 10^4 HNSCC cells in 200ul
complete medium were seeded into the upper compart-
ment of a transwell insert with 8 µm pores (Costar,
Lowell, MA, USA). The lower chamber was filled with 700ul
basal medium containing 10% fetal bovine serum (FBS).
After 12 h (HN6 cell line) or 24 h (CAL27, FADU and
HN4 cell lines), the invaded cells adhering to the lower
compartment were fixed, stained, and counted under
an inverted microscope (Olympus, Tokyo, Japan). For
the invasion assay, 2 × 10^5 cells/well were plated and the
upper compartment was pre-coated with Matrigel (Cor-
ing, Bedford, MA, USA).

Cell viability measurement
Cell viability was detected by CCK-8 assay (Dojindo
Molecular Technologies, Kumamoto, Japan). Cells were
seeded and cultured in 96-well plates at a density of 2000
cells/well. Every other day, CCK-8 reagent was added and
the absorbance was determined at 450 nm.

Wound-healing assay
Cells were seeded into six-well plates and scratched with
a 10ul pipette tip when cells grew to 90% confluence, and
then cells were incubated with complete medium. At 0,
12, or 24 h, wound closure was photographed and its per-
centage was calculated.

Immunofluorescence staining
Cells were plated onto coverslips and fixed in 4% para-
formaldehyde for 20 min when cells grew to 50% con-
fluence. Then, the coverslips were permeabilized with or
without 0.3% Triton, incubated with goat serum for
30 min and primary antibody overnight at 4 °C. After it
was rinsed thrice with PBS with Tween-20, cells were
incubated with fluorescent Cy3 secondary antibodies
(1:50, Proteintech, USA) for 1 h at 37 °C in the dark. After
the slides were incubated with DAPI (Life Technologies,
USA), cells were observed and photographed under an
FV1000 laser confocal scanning microscope (Tokyo,
Japan). Primary antibodies used were as follows: E-cad-
herin (1:100, CST), Vimentin (1:100, CST), and β-catenin
(1:100; CST).

In vivo assay
All animal experiments were in accordance with the Ani-
mal Use and Care Committee of the Affiliated Hospital
of Stomatomy, Nanjing Medical University (IACUC-
1906018). Female 4–6 weeks old BALB/c nude mice used
were purchased from Vital River Laboratory Animal
Technology Co.Ltd (Beijing, China). To explore the role
of FAM83A on HNSCC tumor growth, a total of 2 × 10^6
FAM83A knockdown HN6 cells and control cells were
injected into the right armpit of mice. Tumor growth and
body weight were determined every three days. After
24 days, mice were killed and tumors were stripped care-
fully. To explore the role of FAM83A on HNSCC tumor
metastatic potential, a total of 1 × 10^6 HN6 cells were
injected into the nude mice by tail intravenous. After
42 days, mice lungs were dissected carefully and the
number of metastatic nodes were counted.

Statistical analysis
The chi-square test, Fisher’s exact probability method,
Mann–Whitney U test and Kruskal–Wallis test were
applied to analyze the connection between FAM83A
expression and clinicopathological characteristics. The
Kolmogorov–Smirnov test and paired-samples T test
were applied to compare FAM83A mRNA expression
in HNSCC samples and adjacent normal tissues. Sta-

tistical significance in in vitro and in vivo experiments
was assessed using one-way ANOVA and independent-
samples T test. Data were presented as the mean±SD
from three independent experiments and all data were
analyzed via GraphPad Prism 7 (San Diego, CA, USA)
software. P<0.05 was considered significant in all
experiments.

Results
FAM83A overexpression was associated
with clinicopathological characteristics in HNSCC
To explore the role of FAM83A in HNSCC, we examined
FAM83A expression through 3 tissue microarrays consist-
ing of 242 human HNSCC samples and 12 adjacent nor-
mal tissues through IHC analysis. The expression patterns
of FAM83A in HNSCC and adjacent normal tissues were
classified according to immunoreactive scores and the detailed demographic and clinicopathological parameters of these patients were listed in Table 1. Obviously, HNSCC tissues tended to show stronger cytoplasmic staining of FAM83A and adjacent normal tissues exhibited a lower or negative expression of FAM83A (Fig. 1A–C). We then analyzed the relationship between FAM83A expression and clinicopathological features (Table 1 and Fig. 1D–G). Elevated expressions of FAM83A were detected in tumor samples with bigger tumor size and higher clinical tumor stages (Fig. 1D, F). Besides, advanced HNSCC patients with lymph node metastasis showed higher FAM83A expression levels than those in early-stage patients with no lymph node metastasis (Fig. 1E). However, FAM83A expression has no correlation with pathological classifications (Fig. 1G). Above all, we found that increased FAM83A expression was related to tumor volumes, lymph node status, and clinical tumor stages.

To further clarify the role of FAM83A in HNSCC, we collected 48 pairs of fresh tumor tissues which included HNSCC and adjacent normal tissues. Forty-eight pairs of tissues were used to extract mRNA and 10 pairs of tissues among them were used to extract protein. The qRT-PCR results in 48 HNSCC samples and paired normal tissues demonstrated that FAM83A mRNA was significantly increased in HNSCC than paired normal tissues (Fig. 1H). Among 10 pairs of HNSCC samples and normal tissues, 8 pairs presented higher FAM83A protein levels in tumor tissues (Fig. 1J). FAM83A presented a higher expression level in HNSCC samples than adjacent normal tissues both at mRNA and protein level. Besides, TCGA database showed that the FAM83A mRNA expression is markedly upregulated in 519 HNSCC samples compared to 44 normal tissues (Fig. 1I). Meanwhile, we found that FAM83A expressions in HNSCC cell lines were higher than that in human normal oral keratinocytes (HOK) (Fig. 1K).

FAM83A in HNSCC promoted tumor growth and metastasis in vitro

To further explore the function of FAM83A in HNSCC, we constructed the FAM83A knockdown and overexpression cell lines and verified the efficiency of interference both at the mRNA and protein levels through real-time PCR and western blotting assays. As shown in Fig. 1K, the relatively endogenous FAM83A in CAL27 and FADU cells was higher, and FAM83A in HN4 and HN6 cells was lower. Herein, CAL27 and FADU cells were chosen to be transfected with specific shRNA lentivirus (Fig. 2A, B), while HN4 and HN6 cells were transfected with FAM83A overexpression lentivirus (LV-FAM83A) (Fig. 3A and B). Interestingly, we found that FAM83A knockdown did not change CAL27 and FADU cell morphology (Fig. 2C), but FAM83A overexpression made HN4 and HN6 cells become elongated and fibroblast-like (Fig. 3C). Meanwhile, CCK8 assay found FAM83A downregulation impaired cell viability in CAL27 and FADU cells (Fig. 2D), while, FAM83A upregulation promoted cell growth in HN4 and HN6 cells (Fig. 3D). In the wound healing experiment, the migration of FAM83A knockdown group was significantly slower than those of the negative control group in CAL27 and FADU cell lines (Fig. 2E, F). Conversely, FAM83A overexpression made HN4 and HN6 cells become elongated and fibroblast-like (Fig. 3C). Meanwhile, CCK8 assay found FAM83A downregulation impaired cell viability in CAL27 and FADU cells (Fig. 2D), while, FAM83A upregulation promoted cell growth in HN4 and HN6 cells (Fig. 3D). In the wound healing experiment, the migration of FAM83A knockdown group was significantly slower than those of the negative control group in CAL27 and FADU cell lines (Fig. 2E, F). Conversely, FAM83A overexpression group enhanced the migratory ability in HN4 and HN6 cells lines (Fig. 3E, F). Besides, transwell assays showed that the downregulation of FAM83A significantly weakened the migratory and invasive ability in CAL27 and FADU cell lines (Fig. 2G, H) and FAM83A upregulation significantly enhanced the migratory and invasive ability in HN4 and HN6 cell lines (Fig. 3G and H). These results indicated FAM83A promoted HNSCC cells growth and metastasis in vitro.

### Table 1

| Pathologic characteristics | n    | FAM83A expression (number of cases) | P value |
|---------------------------|------|------------------------------------|---------|
|                           |      | Low      | High     |         |
| Age, years                |      |          |          |         |
| ≥ 60                      | 118  | 88       | 30       | 0.2412  |
| < 60                      | 124  | 84       | 40       |         |
| Sex                       |      |          |          |         |
| Male                      | 148  | 115      | 33       | 0.0056  |
| Female                    | 94   | 57       | 37       |         |
| Tumor size                |      |          |          |         |
| T1                        | 109  | 87       | 22       | 0.0399  |
| T2                        | 95   | 63       | 32       |         |
| T3                        | 24   | 14       | 10       |         |
| T4                        | 14   | 8        | 6        |         |
| Lymph node status         |      |          |          |         |
| N0                        | 130  | 108      | 22       | <0.0001 |
| N1                        | 41   | 31       | 10       |         |
| N2                        | 27   | 17       | 10       |         |
| N3                        | 44   | 16       | 28       |         |
| Pathological grade        |      |          |          |         |
| I                         | 136  | 99       | 37       | 0.2984  |
| II                        | 81   | 53       | 28       |         |
| III                       | 25   | 20       | 5        |         |
| Clinical stage            |      |          |          |         |
| I                         | 64   | 52       | 12       | 0.0983  |
| II                        | 51   | 36       | 15       |         |
| III                       | 35   | 26       | 9        |         |
| IV                        | 92   | 58       | 34       |         |
FAM83A promoted EMT and activated Wnt/β-catenin signaling pathway in HNSCC cells

The morphological and functional results induced by FAM83A suggested FAM83A may be an important facilitator of EMT in HNSCC. Herein, we determined EMT-related markers expression through western blotting, real-time PCR and immunofluorescence assays after FAM83A silencing and overexpression. As shown in Fig. 4A–H, after FAM83A was knocked down in CAL27
and FADU cells, the epithelial marker E-cadherin was elevated and the mesenchymal markers including N-cadherin, Vimentin and Snail descended at both protein and mRNA levels (Fig. 4A–C). As expected, FAM83A overexpression exerted the opposite effects in HN4 and HN6 cell lines (Fig. 4G, H). Besides, we found FAM83A could enhance Wnt-responsive genes expression. As shown in Fig. 4A–F, FAM83A knockdown group cells showed the downregulation of c-myc and Cyclin D1 and the upregulation of phosphor-β-catenin. Meanwhile, FAM83A overexpression group cells showed the upregulation of c-myc and Cyclin D1 and the downregulation of phosphor-β-catenin compared to the negative control group. However, FAM83A did not affect total β-catenin expression in HNSCC cells (Fig. 4A–F). Taken together,
FAM83A promoted EMT and activated Wnt/β-catenin signaling pathway in HNSCC cell lines.

FAM83A promoted EMT through Wnt/β-catenin signaling pathway and β-catenin regulated FAM83A expression in HNSCC cells

To further explore the possible mechanism of FAM83A in regulating the proliferation, migration, and invasion of HNSCC, we detected β-catenin changes in nucleus and cytoplasm. Western blotting analysis demonstrated nuclear β-catenin decreased while cytosolic β-catenin increased after FAM83A knockdown in CAL27 and HN6 cells. Meanwhile, β-catenin increased in the nucleus and decreased in the cytoplasm when FAM83A was overexpressed (Fig. 5A and B). Besides, immunofluorescence assay of β-catenin showed lower level of nuclear β-catenin in the FAM83A knockdown groups and higher level of nuclear β-catenin in the FAM83A-overexpressing groups in CAL27 and HN6 cells (Fig. 5C, D). These phenomena further indicated that FAM83A promoted β-catenin...
nuclear translocation and activated the Wnt/β-catenin signaling pathway. We treated HNSCC cells with 50 μmol XAV-939 which could suppress exogenous β-catenin expression and we observed the cell viability, migration and invasion ability all decreased after the treatment with XAV-939 in CAL27 and HN6 cells (Additional file 1: Figure S1A–C). At the same time, western blotting assay found that E-cadherin expression was increased, N-cadherin, Vimentin and Snail expression were decreased when CAL27 and HN6 FAM83A-overexpression group cells were treated with XAV-939 (Fig. 5E). Interestingly, the downregulation of β-catenin induced by XAV-939 Fig. 4 FAM83A promotes EMT and activates Wnt/β-catenin signaling pathway in HNSCC cells. A Protein levels of FAM83A, E-cadherin, N-cadherin, Vimentin, Snail and Wnt-responsive genes including β-catenin, phosphor-β-catenin, c-myc and Cyclin D1 were determined by western blotting in CAL27 and FADU cells after shFAM83A transfection. B, C Gene expressions of FAM83A, E-cadherin, N-cadherin, Vimentin, Snail, c-myc and Cyclin D1 were measured by RT-PCR in CAL27 and FAUD cells after shFAM83A transfection. D Protein levels of FAM83A, E-cadherin, N-cadherin, Vimentin, Snail and Wnt-responsive gene including β-catenin, phosphor-β-catenin, c-myc and Cyclin D1 were determined by western blotting in HN4 and HN6 cells after LV-FAM83A transfection. E, F Gene expressions of FAM83A, E-cadherin, N-cadherin, Vimentin, Snail and c-myc and Cyclin D1 were measured by RT-PCR in HN4 and HN6 cells after LV-FAM83A transfection. G Immunofluorescence analysis of the EMT marker E-cadherin and Vimentin in CAL27 cells after shFAM83A transfection (200 ×). H Immunofluorescence analysis of the EMT marker E-cadherin and Vimentin in HN6 cells after LV-FAM83A transfection (200 ×). Data represent the mean ± SD; *p < 0.05, **p < 0.01, ***p < 0.001
decreased FAM83A protein expression (Fig. 5E). This suggests that β-catenin could also regulate FAM83A. To further prove it, we treated CAL27 and HN6 cells with small interfering RNA (siRNA) of β-catenin and a plasmid containing the β-catenin cDNA sequence respectively. As shown in Fig. 5F and Additional file 2: Figure
S2A–D, β-catenin silencing caused FAM83A downregulation and β-catenin overexpression resulted in FAM83A upregulation both at protein and mRNA level. Taken together, the above findings suggested that FAM83A promotes cell proliferation and metastasis in HNSCC by activating Wnt/β-catenin signaling pathway and there may be a loop feedback between FAM83A and β-catenin.

**FAM83A promoted tumor growth and distant metastasis in vivo**

To study the function of FAM83A on tumor growth in HNSCC, we used a subcutaneous xenograft tumor model and injected HN6 cells (2 × 10⁶) into the right flank of mice. Compared with the tumors produced by the negative control cells, the tumors separated from mice injected with the FAM83A-knockdown cells were smaller and showed a weaker ability in tumor growth (Fig. 6A). The tumors formed in the negative control group possessed a larger tumor volume and heavier weight than shFAM83A group (Fig. 6B, C). HE staining assay demonstrated the tumors separated from nude mice were HNSCC (Fig. 6D). Besides, IHC assay demonstrated tumors dissected from negative control group had a stronger FAM83A staining compared with the other group (Fig. 6E). Moreover, we used an experimental metastasis assay to explore its function on tumor potential metastasis and injected HN6 cells (1 × 10⁶) into the tail intravenous of nude mice. As described in Fig. 6F and G, mice injected with shFAM83A group cells formed less pulmonary metastases (n = 6, an average of 3 nodules per...

---

**Fig. 6** FAM83A knockdown inhibits HNSCC growth and metastasis in nude mice. **A** The shFAM83A cells and control cells were subcutaneously injected into nude mice and general observation of tumor-bearing nude mice injected with cells. **B** Volumes of xenograft tumors in shNC and shFAM83A groups. **C** Tumor tissues in shNC and shFAM83A groups were weighed after 24 days. **D** Representative showings of tumors formed in the nude mice were diagnosed as HNSCC by HE staining (100 x). **E** Representative photomicrographs of positive staining of FAM83A in shNC groups and negative staining of FAM83A in shFAM83A groups (100 x). **F, G** Representative photographs of lung tissues in mice injected with shFAM83A cells and shNC cells and a summary of the number of lung metastatic nodules in shFAM83A and shNC groups. **H** HE staining of lung tissues in shNC and shFAM83A groups (H1, H3, 100 x; H2, H4, 200 x). Data represent the mean ± SD; *p < 0.05, **p < 0.01, ***p < 0.001.
demonstrated that the number of metastatic lesions significant declined in shFAM83A group mice compared with shNC group (Fig. 6H). These findings suggested that FAM83A promoted tumor growth and metastasis in HNSCC.

**Discussion**

HNSCC is a malignant tumor with high mortality rate [1, 2]. The carcinogenesis of HNSCC is complex which involves coefficient functions of multiple feedback loops and cross-talk communications. Different genetic alterations interact with each other and will be taken into consideration to guide the targeted therapy in HNSCC. Previous studies have highlighted that the up-regulated FAM83A often functions as an oncogenic gene in tumorigenesis. However, the function of FAM83A in HNSCC has not been reported and particularly requires further exploration.

In our study, the function and mechanism of FAM83A in HNSCC were profoundly investigated. Firstly, immunohistochemistry in human HNSCC microarrays showed aberrant overexpression of FAM83A in a large number of patients compared with adjacent normal tissues. It is interesting to note that FAM83A positivity was observed as brown membranous and cytoplasmic immunostaining in HNSCC group, consistent with the previous reports [15]. Our results showed that FAM83A expression was positively correlated with advanced tumor size, lymph node metastasis, and clinical tumor stages respectively. The clinical specimens showed that FAM83A may play a key role in the migration and metastasis of HNSCC in the present study. Then, FAM83A expression was noticeably amplified in HNSCC fresh tissues and cells by RT-qPCR and Western Blotting. This was consistent with the results of TCGA database, indicating that HNSCC samples have higher expressions of FAM83A than those in adjacent tissues. Therefore, FAM83A might serve as an oncogene in HNSCC.

The mechanism of FAM83A in promoting HNSCC progression is not clear. To explore the underlying mechanism of FAM83A in HNSCC cells, we constructed stably transfected FAM83A knockdown and overexpressed HNSCC cells. Depletion of FAM83A dramatically inhibited cell proliferation, migration, and invasion in HNSCC cells. Moreover, we found that knockdown of FAM83A expression in HNSCC cells decreased metastatic foci in vivo. FAM83A overexpression exerted the opposite effects. All these results illustrated that the up-regulation of FAM83A could enhance cell proliferation, migration and invasion in HNSCC. Taken together, these data indicate that FAM83A could promote HNSCC progression.

The epithelial to mesenchymal transition (EMT) plays a vital role in cancer metastasis [26, 27]. The down-regulation of epithelium markers such as E-cadherin and the up-regulation of mesenchymal marker such as N-cadherin, Vimentin and Snail are the most common hallmarks of EMT [28]. Prior studies have indicated that the initiation of EMT in tumor is frequently observed in the metastasis of HNSCC [29]. In our study, HNSCC cells presented fibroblast-like phenotypes, showing a more elongated and spindle-like shape in HNSCC cells after FAM83A overexpression. Also, E-cadherin was increased while N-cadherin, Vimentin, and Snail were inhibited after silencing FAM83A in CAL27 and FADU cell lines, which suggested that the EMT of HNSCC was inhibited. All these data suggested that FAM83A can induce the activation of the EMT-related signaling pathways in HNSCC cells. Therefore, FAM83A might play a vital role in the EMT of HNSCC.

It is suggested that aberrant changes of Wnt/β-catenin signaling pathway are of decisive importance in EMT [30]. Wnt can activate β-catenin at a downstream location in the Wnt/β-catenin signaling [31]. The Wnt/β-catenin signaling pathway can play a key role in cell proliferation, differentiation and regeneration [32]. The upregulation of β-catenin plays an important role in enhancing the invasion and metastasis of several types of cancer by inducing EMT. GSK3β phosphorylates β-catenin and results in the degradation of β-catenin, which inhibits the activity of the Wnt signaling pathway [30–32]. Interestingly, it has been reported that the overexpression of FAM83A could interact with the Wnt/β-catenin signaling pathway in pancreatic cancer and lung cancer [6].

To explore the underlying mechanism of FAM83A in HNSCC cells, we examined the effects of FAM83A on the Wnt signaling pathway and EMT. It is reported that c-myc elevated oncogenic activity provided an upregulation of EMT in HNSCC [33].

Our study showed that FAM83A can enhance the expression of active β-catenin and downstream targets of the Wnt pathway, such as cyclin D1 and c-myc. Besides, western blotting assays and immunofluorescence staining assays demonstrated that β-catenin entered into the cell nucleus from the cytoplasm in CAL27 and HN6 FAM83A-upregulated cells, demonstrating the Wnt-pathway-mediated β-catenin activation. These results were further demonstrated by using the β-catenin inhibitor to pharmacologically block the Wnt signaling pathway. In the rescue experiment, the inhibitor, XAV-939, could reverse the promoting effect of FAM83A in HNSCC. It is known that FAM83F and FAM83G can regulate canonical Wnt signaling through an interaction with CK1α [22]. Previous research also proposed that FAM83A can inhibit GSK3β activity and increase the
level of active unphosphorylated β-catenin and active β-catenin can transports into the nucleus thus activating the Wnt signaling pathway in lung cancer [23]. Thus, we suspect that FAM83A can similarly lead to aberrant activation of Wnt/β-catenin signaling through its interaction with CK1α and GSK3β in HNSCC. FAM83A can activate β-catenin, leading to the transporting into the nucleus of HNSCC cells. This possibility is under investigation in the lab.

In this study, we found that β-catenin inhibitor could also downregulate the mRNA and protein level of FAM83A in CAL27 and HN6 cells. Furthermore, we found that the overexpression of β-catenin can result in the upregulation of mRNA and protein level of FAM83A. However, there is no β-catenin/TCF/LEF binding site in FAM83A promoter. The fact that the expressions of FAM83A and β-catenin are positively correlated could be explained by the fact that β-catenin can regulate FAM83A through other relative pathways. We think there are possible binding sites of the downstream genes of Wnt/β-catenin in FAM83A promoter. The underlying mechanism needs further investigation.

In general, we presented evidence for the first time that overexpression of FAM83A in HNSCC tissues was positively correlated with advanced tumor size, lymph node metastasis and clinical tumor stages. Besides, the present study is the first to provide evidence that the Wnt-β-catenin-mediated EMT and metastasis by FAM83A in HNSCC, and there may be a potential bi-directional signaling loop between FAM83A and Wnt/β-catenin signaling pathway (Additional file 3: Figure S3). Therefore, understanding the molecular mechanism by which FAM83A activates Wnt signaling pathway in HNSCC will increase our knowledge of the biological basis of HNSCC and may enable the potential strategies for HNSCC. Our research provides a novel target for the early diagnosis and treatment in HNSCC patients.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12967-021-03089-6.

Acknowledgements

All authors are acknowledged for their contribution to the study.

Authors’ contributions

YZ and HW designed this experiment. HJ, HS, ZW, and PJ performed all procedures of experiments. JX, XL and HD analyzed data. YZ and HW wrote the manuscript. All authors edited and approved the manuscript.

Funding

The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Nature Science Foundation of Jiangsu Province (Grants No BK20180669), and the Health Committee of Jiangsu Province (Grants No MZ200003).

Availability of data and materials

The datasets generated and/or analyzed during the current study are not publicly available but are available from the corresponding author upon reasonable request.

Declarations

Ethics approval and consent to participate

This study was approved by the ethical committee of the Nanjing Medical University. All cell donors signed informed consent documents. The authors declare that they have no conflict of interest.

Consent for publication

Not applicable.

Competing interests

The authors have no competing interests to declare.

Author details

1 Jiangsu Province Key Laboratory of Oral Diseases, School of Stomatology, Nanjing Medical University, Nanjing, China. 2 Jiangsu Province Engineering Research Center of Stomatological Translational Medicine, School of Stomatolgy, Nanjing Medical University, Nanjing, China. 3 Department of Oral and Maxillofacial Surgery, The Affiliated Stomatological Hospital of Nanjing Medical University, Nanjing, China. 4 Department of General Dentistry, Department of Oral Medicine, The Affiliated Stomatological Hospital of Nanjing Medical University, #136 Hanzhong Road, Nanjing 210029, Jiangsu, China.

Received: 25 February 2021 Accepted: 26 September 2021

Published online: 12 October 2021

References

1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.
2. Zhang XM, Song LJ, Shen J, et al. Prognostic and predictive values of immune infiltrate in patients with head and neck squamous cell carcinoma. Hum Pathol. 2018;82:104–12.
3. Li Y, Dong X, Yin Y, et al. BJ-TSA-9, a novel human tumor-specific gene, has potential as a biomarker of lung cancer. Neoplasia. 2005;7:1073–80.
4. Snijders AM, Lee SY, Hang B, et al. FAM83 family oncogenes are broadly involved in human cancers: an integrative multi-omics approach. Mol Oncol. 2017;11:167–79.
5. Bartel CA, Jackson MW. HER2-positive breast cancer cells expressing elevated FAM83A are sensitive to FAM83A loss. PLoS ONE. 2017;12:e0176778.
6. Chen S, Huang J, Liu Z, et al. FAM83A is amplified and promotes cancer stem cell-like traits and chemoresistance in pancreatic cancer. Oncogene. 2017;36.e300.

7. Cipriano R, Miskimen KL, Bryson BL, et al. Conserved oncogenic behavior of the FAM83 family regulates MAPK signaling in human cancer. Mol Cancer Res. 2014;12:1156–65.

8. Grant S. FAM83A and FAM83B: candidate oncogenes and Tki resistance mediators. J Clin Invest. 2012;122:3048–51.

9. Lee SY, Meier R, Furuta S, et al. FAM83A confers EGR-TRi resistance in breast cancer cells and in mice. J Clin Invest. 2012;122:3211–20.

10. Liu L, Liao GQ, He P, et al. Detection of circulating cancer cells in lung cancer patients with a panel of marker genes. Biochem Biophys Res Commun. 2008;372:756–60.

11. Liu L, Ma C, Xu Q, et al. A rapid nested polymerase chain reaction method to detect circulating cancer cells in breast cancer patients using multiple marker genes. Oncol Lett. 2014;7:2192–8.

12. Xu J, Lu W. FAM83A exerts tumorsuppressive roles in cervical cancer by regulating integrins. Int J Oncol. 2020;57:509–21.

13. Zhou F, Wang X, Liu F, et al. FAM83A drives PD-L1 expression via ERK signaling and FAM83A/PD-L1 co-expression correlates with poor prognosis in lung adenocarcinoma. Int J Clin Oncol. 2020;25:1612–23.

14. Richtmann S, Willens D, Warth A, et al. FAM83A and FAM83B as prognostic biomarkers and potential new therapeutic targets in NSCLC. Cancers (Basel). 2019;11:562.

15. Zhang JT, Lin YC, Xiao BF, et al. Overexpression of family with sequence similarity 83, member A (FAM83A) predicts poor clinical outcomes in lung adenocarcinoma. Med Sci Monit. 2019;25:4624–72.

16. Zhou F, Geng J, Xu S, et al. FAM83A signaling induces epithelial-mesenchymal transition by the PI3K/AKT/Snail pathway in NSCLC. Aging (Albany NY). 2019;11:6069–88.

17. Fulcher LJ, Bozatzi P, Tachie-Menson T, et al. The DUF1669 domain of FAM83 family proteins anchor casein kinase 1 isoforms. Sci Signal. 2018;11:eaao2341.

18. Schittek B, Sinnberg T. Biological functions of casein kinase 1 isoforms and putative roles in tumorigenesis. Mol Cancer. 2014;13:231.

19. Cruciat CM. Casein kinase 1 and Wnt/beta-catenin signaling. Curr Opin Cell Biol. 2014;31:46–55.

20. Jiang S, Zhang M, Sun J, et al. Casein kinase 1alpha: biological mechanisms and theranostic potential. Cell Commun Signal. 2018;16:23.

21. Philpott JM, Narasimamurthy R, Ricci CG, et al. Casein kinase 1 dynamics underlie substrate selectivity and the PER2 circadian phosphoswitch. Elife. 2020;9:e52343.

22. Dunbar K, Jones RA, Dingwell K, et al. FAM83F regulates canonical Wnt signaling through an interaction with CK1alpha. Life Sci Alliance. 2021;4:e20200805.

23. Zheng YY, Li ZH, Lei L, et al. FAM83A promotes lung cancer progression by regulating the Wnt and hippo signaling pathways and indicates poor prognosis. Front Oncol. 2020;10:180.

24. Zheng Y, Wang C, Song A, et al. CMT/M6 promotes cell proliferation and invasion in oral squamous cell carcinoma by interacting with NRP1. Am J Cancer Res. 2020;10:1691–709.

25. Ji H, Ding X, Zhang W, et al. Claudin-7 inhibits proliferation and metastasis in salivary adenoid cystic carcinoma through Wnt/β-catenin signaling. Cell Transplant. 2020;29:0963689720943588.

26. Lambert AW, Pattabiraman DR, Weinberg RA. Emerging biological principles of metastasis. Cell. 2017;168:670–91.

27. Pastushenko I, Blanpain C. EMT transition states during tumor progression and metastasis. Trends Cell Biol. 2019;29:212–26.

28. Serrano-Gomez SJ, Maziveyi M, Alahari SK. Regulation of epithelial-mesenchymal transition through epigenetic and post-translational modifications. Mol Cancer. 2016;15:18.

29. Therauf J, Veit JA, Hess J. Epithelial-to-mesenchymal transition in the pathogenesis and therapy of head and neck cancer. Cancers (Basel). 2017;9:76.

30. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15:178–96.

31. Gruber J, Yee Z, Tolwinski NS. Developmental drift and the role of Wnt signaling in aging. Cancers (Basel). 2016;8:73.

32. Shi J, Chi S, Xue J, et al. Emerging role and therapeutic implication of Wnt signaling pathways in autoimmune diseases. J Immunol Res. 2016;2016:9392132.

33. Inamura N, Kimura T, Wang L, et al. Notch1 regulates invasion and metastasis of head and neck squamous cell carcinoma by inducing EMT through c-Myc. Auris Nasus Larynx. 2017;44:447–57.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.